GLS 5300

Drug Profile

GLS 5300

Alternative Names: GLS-5300; MERS DNA vaccine - Inovio Pharmaceuticals

Latest Information Update: 09 Aug 2016

Price : $50

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer GeneOne Life Science; Inovio Pharmaceuticals; Walter Reed Army Institute of Research
  • Class Antivirals; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Middle East respiratory syndrome coronavirus

Most Recent Events

  • 08 Aug 2016 GeneOne completes enrolment in its phase I trial for Middle East respiratory syndrome coronavirus (Prevention) in USA
  • 28 Jan 2016 Phase-I clinical trials in Middle East respiratory syndrome coronavirus (Prevention) in USA (Parenteral)
  • 19 Nov 2015 FDA approves a phase I trial of GLS 5300 for Middle Eastern respiratory syndrome coronavirus infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top